Strategic Analysis of Corporate Excise Due (Before Credits) within the Massachusetts Research and Development Tax Credit Framework

Corporate Excise Due (Before Credits) represents the total tax liability arising from a company’s income and property measures prior to the application of any tax incentives or offsets. It serves as the statutory baseline used to determine the maximum value of the Research and Development credit that can be applied in a given tax year.

The Massachusetts corporate tax system is uniquely structured as a dual-measure excise, taxing both the net income and the property or net worth of a business entity.1 For tax professionals and corporate strategists, the figure termed “Excise Due (Before Credits)” is not merely a line item on a return but a critical anchor that governs the liquidity and utilization of one of the Commonwealth’s most potent innovation incentives: the Research Credit under M.G.L. c. 63, § 38M.3 This report explores the mechanical, legal, and strategic dimensions of this figure, detailing how it interacts with state revenue guidance and the broader mission of fostering a technological hub in Massachusetts.

The Structural Anatomy of the Massachusetts Corporate Excise

To understand the meaning of “Before Credits” in the corporate excise context, it is necessary to dissect the components that constitute the baseline tax liability of a Massachusetts corporation. Unlike states that utilize a simple corporate income tax, Massachusetts employs an “excise” which is theoretically a tax on the privilege of doing business as a corporation in the state.5 This privilege is quantified through two distinct lenses: the income measure and the non-income (property or net worth) measure.7

The income measure is generally calculated as a percentage of the net income apportioned to Massachusetts. For most general business C-corporations, the applicable rate is 8.00%.1 This calculation begins with federal gross income and incorporates specific Massachusetts modifications, such as the add-back of state and municipal bond interest and the adjustment of certain federal deductions that the Commonwealth does not recognize.7 Following these adjustments, an apportionment formula is applied to determine the portion of the corporation’s income that is subject to the Massachusetts tax.2

The non-income measure, conversely, ensures that even corporations with low or no taxable income still contribute to the state’s revenue if they maintain a significant physical or financial presence.1 This measure is calculated at a rate of $2.60 per $1,000 of the value of either the corporation’s Massachusetts tangible property or its net worth.7 The classification of a corporation as “tangible” or “intangible” for this purpose depends on the ratio of its Massachusetts tangible property to its total assets.2

Table 1: Standard Corporate Excise Rates and Statutory Thresholds

The summation of these measures, along with specific additions such as credit recapture taxes and additional taxes on installment sales, forms the “Excise Due (Before Credits)”.10 On the 2024 Form 355, this value is finalized on Line 6 of the Excise Calculation section.10 This figure represents the corporation’s gross liability before any incentives from the “Credit Manager Schedule” (Schedule CMS) are subtracted.5

The Research and Development Tax Credit: M.G.L. c. 63, § 38M

The Massachusetts Research Credit is the primary mechanism through which the state incentivizes private investment in innovation.3 Codified under M.G.L. c. 63, § 38M, the credit is explicitly modeled after the federal research credit available under Section 41 of the Internal Revenue Code (IRC).3 However, while the federal credit has often been subject to temporary extensions, the Massachusetts credit is a permanent fixture of the state’s tax code.15

To qualify for the credit, a corporation must incur “qualified research expenses” (QREs) within the borders of Massachusetts.15 These expenses typically include the wages of employees directly involved in research, supplies used in the laboratory or development environment, and 65% of the costs associated with contract research performed in-state.12 The state further differentiates between general research and basic research, the latter of which involves payments to qualified organizations such as universities or scientific research institutes.4

Calculation Methodologies: Traditional vs. Alternative Simplified

Taxpayers in Massachusetts have two primary options for calculating the Research Credit, a flexibility introduced to simplify compliance for firms with varying historical data availability.16

The Traditional Method calculates the credit as 10% of the excess of the current year’s QREs over a “base amount”.3 The base amount is derived by multiplying the corporation’s average annual gross receipts for the preceding four years by a “fixed-base ratio”.4 For many years, calculating this ratio was administratively burdensome as it required records dating back to the 1980s.16 In response to these challenges, the legislature modernized the calculation on a rolling basis and introduced the Alternative Simplified Method (ASM) for tax years beginning in 2015.14

The ASM allows a corporation to elect a credit based on its current research spending relative to its own recent history.14 For tax years beginning on or after January 1, 2021, the ASM credit is equal to 10% of the QREs that exceed 50% of the average QREs from the three prior taxable years.3 If a corporation has no QREs in any of the three prior years, the credit is limited to 5% of the current year’s QREs.4

Table 2: Comparison of Research Credit Calculation Options

The Mechanics of Limitation: Why “Before Credits” is the Anchor

The most critical regulatory intersection for any taxpayer claiming the Research Credit is the “75% limitation” rule.3 This rule defines the maximum amount of the calculated credit that can actually be used to reduce the tax bill in any given year. The “Corporate Excise Due (Before Credits)” is the specific number upon which this entire limitation math is anchored.3

The Statutory Cap on Credit Utilization

Under M.G.L. c. 63, § 38M(d), the research credit is limited to:

• 100% of the corporation’s first $25,000 of excise (as determined before any credits).4
• 75% of the corporation’s excise that exceeds $25,000.4

Furthermore, the credit cannot reduce the corporation’s liability below the minimum excise of $456.3 This structure creates a “tiered” utilization system where the first $25,000 of liability is effectively “soft” (fully offsettable), while everything above that threshold is “harder” to offset, requiring the corporation to pay at least 25% of that excess excise in cash to the Commonwealth.13

The mathematical representation of the maximum allowable credit utilization ($C_{util}$) relative to the excise before credits ($E_{bc}$) is:

$$C_{util} \le 25,000 + 0.75 \times (E_{bc} – 25,000)$$

If a company’s $E_{bc}$ is $100,000, the maximum credit it can use is $25,000 + 0.75 \times (75,000)$, which equals $81,250. This means that even if the company has $1,000,000 in R&D credits, it must still pay $18,750 in tax ($100,000 – $81,250) for that year.14

Table 3: Impact of 75% Limitation on Net Excise Due

This policy reflects a deliberate balancing act by the Massachusetts legislature. While it seeks to reward innovation, it also ensures that large, profitable corporations contribute a baseline level of revenue to support state infrastructure and services, regardless of the intensity of their R&D spending.3

Local State Revenue Office Guidance and the Regulatory Environment

The Massachusetts Department of Revenue (DOR) has issued a series of authoritative documents that clarify how corporations should interpret these statutes. For a business to remain compliant while maximizing its credit position, it must navigate Technical Information Releases (TIRs), Directives, and Regulations.

Technical Information Release (TIR) 91-8

TIR 91-8 remains a foundational piece of guidance, issued shortly after the credit’s inception.23 It established the essential procedural requirement that corporations must file Schedule RC to substantiate the computation of the credit.23 It also clarified that research expenses are considered “incurred” for Massachusetts purposes if they are treated as such for federal income tax purposes.23 This alignment with federal standards reduces the accounting burden on companies, allowing them to use a single set of QRE tracking for both state and federal filings.12

830 CMR 63.38M.1 and 63.38M.2

These regulations provide the comprehensive “rulebook” for the credit. Regulation 830 CMR 63.38M.2 is particularly relevant for modern businesses as it addresses the 2015 legislative changes and the introduction of the ASM.20 It defines the “qualified research base amount” and the “fixed-base ratio” in great detail, providing the mathematical formulas required for the Traditional Method.20

The regulation also addresses the concept of “aggregated groups”.20 Because the $25,000 threshold (the 100% offset tier) is a significant benefit, the DOR requires corporations under common control to share a single $25,000 amount.14 This prevents a single business from splitting into ten separate legal entities just to claim ten separate $25,000 full offsets.19

DOR Directive 01-9: Recapture Tax Interaction

A significant insight for tax planners is found in DOR Directive 01-9, which discusses how the “recapture tax” interacts with current year credits.11 If a corporation disposes of property for which it previously took an Investment Tax Credit (ITC) or Brownfields credit, it must “recapture” that credit as additional tax.11 Directive 01-9 allows the corporation to add this recapture tax to its standard excise when calculating the baseline for credit application.11 This effectively increases the “Excise Before Credits” figure, thereby increasing the 75% limitation cap and potentially allowing for greater utilization of the Research Credit in a high-recapture year.11

The Dual Carryover System: A Strategic Reserve

One of the most valuable, yet frequently misunderstood, features of the Massachusetts Research Credit is its bifurcated carryover rules.3 The state distinguishes between credits that are unused because they exceed the total excise and credits that are disallowed specifically because of the 75% rule.15

The 15-Year Standard Carryover

If a corporation’s calculated Research Credit is simply larger than its total tax liability, the unused portion may be carried forward for up to 15 years.3 For example, if a startup has $0 in excise liability (subject to the $456 minimum) but earns $50,000 in R&D credits, those credits enter the 15-year carryover pool.3

The Indefinite (Unlimited) Carryover

A unique provision in M.G.L. c. 63, § 38M(f) allows for an “unlimited” carryover period for credits that are disallowed specifically by the 75% limitation.3 If a company has enough excise to use the credit, but the law steps in and says “you can only offset 75% of the excess,” the disallowed 25% does not expire in 15 years—it lasts forever.3

This distinction is crucial for long-term tax planning. It essentially creates two separate buckets of credits on a company’s “deferred tax asset” ledger. The 15-year bucket requires aggressive near-term utilization, while the indefinite bucket acts as a permanent hedge against future Massachusetts tax liabilities, ensuring that the economic value of the R&D investment is never truly lost to the “treadmill” of expiration.3

Form 355 Instructions and the Path to Compliance

For a corporation to successfully claim and utilize the Research Credit, it must follow a rigorous filing sequence. The “Excise Before Credits” figure is the culmination of several schedules and calculations that must be accurate before Schedule RC can be applied.5

Step-by-Step Filing Sequence

1. Calculate the Property Measure: The corporation completes Schedule A to determine its taxable tangible property or net worth.5 This provides the figure for Line 1 or Line 2 of the Excise Calculation.10
2. Calculate the Income Measure: The corporation completes Schedule E to determine its Massachusetts taxable income, which is then multiplied by 8.00%.5 This is entered on Line 3.10
3. Account for Recaptures and Additions: Any credit recapture (Line 4) or additional tax on installment sales (Line 5) is added to the previous figures.10
4. Finalize Excise Before Credits: The sum of Lines 1 through 5 is entered on Line 6.10
5. Apply Schedule RC: The corporation then calculates its Research Credit on Schedule RC, keeping in mind the 75% limit based on the Line 6 amount.14
6. Report on Schedule CMS: Finally, the allowable portion of the credit is reported on the Credit Manager Schedule (CMS), which feeds back into the main Form 355 to determine the “Excise Due After Credits”.5

Table 4: Key Forms and Schedules for R&D Compliance

Aggregated Groups and Combined Reporting: The 355U Factor

For many large enterprises, Massachusetts tax is not a single-company affair. Massachusetts requires corporations engaged in a “unitary business” under common control to file a combined report on Form 355U.6 In this context, the “Excise Due (Before Credits)” is calculated for the group, but the non-income measure is still determined on a separate company basis.6

The Sharing of Excess Credits

One of the most powerful aspects of the combined reporting regime is the ability to share credits.4 If one member of a combined group (Corporation A) generates $500,000 in R&D credits but only has $100,000 in excise, it may be able to “share” its excess credits with Corporation B, another member of the group that has a high tax liability but no R&D of its own.4 However, the law is clear: the shared credit cannot be used to bypass the 75% limitation or the $456 minimum excise for the receiving corporation.4 This ensures that the consolidated group still pays its fair share of tax while allowing for the efficient use of innovation incentives across different legal entities.19

Comprehensive Illustrative Example: BioTech Solutions, Inc.

To see these rules in action, consider BioTech Solutions, Inc., a C-corporation headquartered in Cambridge with significant R&D and a growing manufacturing presence in the state for the 2024 tax year.

Calculation of Excise Before Credits

BioTech Solutions performs its preliminary tax calculations:

• Income Measure: The company has $5,000,000 in Massachusetts taxable income. At an 8% rate, the income measure tax is $400,000.
• Property Measure: As a manufacturer, it has $10,000,000 in taxable tangible property. At $2.60 per $1,000, the property measure tax is $26,000.
• Total Excise Before Credits (Line 6): $400,000 + $26,000 = $426,000.

Calculation of the Research Credit (Traditional Method)

BioTech Solutions has a long history and prefers the Traditional Method:

• Current Year QREs: $4,500,000.
• Base Amount: Based on its prior 4 years of receipts and fixed-base percentage, its base amount is calculated to be $2,000,000. (Note: This is higher than the minimum base of 50% of current QREs, which would be $2,250,000. Therefore, the base amount used is actually $2,250,000).
• Incremental QREs: $4,500,000 – $2,250,000 = $2,250,000.
• Calculated Credit: 10% of $2,250,000 = $225,000.

Application of the 75% Limitation

The company must now apply the limitation formula to its $426,000 baseline:

1. First Tier: The first $25,000 is 100% offsettable. (Available: $25,000).
2. Second Tier: The excess excise is $426,000 – $25,000 = $401,000.
3. Allowable Offset for Second Tier: 75% of $401,000 = $300,750.
4. Total Allowable Credit Use: $25,000 + $300,750 = $325,750.

Final Result for BioTech Solutions

• Net Tax Due: Since the company only has $225,000 in total credits, and the limit is $325,750, it can use the entire $225,000 in the current year.
• Final Excise After Credits: $426,000 – $225,000 = $201,000.
• Carryover: There is no carryover for this year as all credits were consumed.

If the company had $500,000 in credits, it would use $325,750, pay $100,250 in tax, and carry forward $174,250. Of that carryforward, the portion disallowed specifically by the 75% rule ($75,250, which is 25% of the $300,750 tier) would have an indefinite life.3

Economic Impact and Legislative Intent: Statistics and Outlook

The Research Credit is a cornerstone of the Massachusetts “Tax Expenditure Budget,” which tracks the revenue the Commonwealth foregoes to support specific policy goals.8 In fiscal year 2025, the total corporate excise tax is projected to generate approximately $3.5 billion in revenue.28 A significant portion of this revenue is “offset” by credits, with the Research Credit being one of the largest.29

Table 5: Massachusetts Fiscal Overview (FY 2024-2025 Projection)

Statistically, the Massachusetts economy is heavily weighted toward high-innovation sectors.30 Manufacturing and professional services (including software and biotech) are among the largest contributors to the state’s GDP.30 The R&D tax credit is strategically designed to support these sectors. For instance, the expansion of “defense-related activities” to include medical supplies and vaccines in 2024 demonstrates how the state uses the § 38M framework to respond to current public health and security needs.14

The 2025 Shift: Single Sales Factor Apportionment

Looking forward, a major change is coming to how the “Excise Due (Before Credits)” is calculated. Effective for tax years beginning on or after January 1, 2025, Massachusetts is moving to a “single sales factor” apportionment for all corporations.5 Previously, many companies used a three-factor formula (property, payroll, and sales).2

This shift will significantly impact R&D companies that have most of their “feet on the ground” (property and payroll) in Massachusetts but sell their products globally.6 For these firms, the “Excise Before Credits” is likely to decrease because their out-of-state sales will now be the only factor used to apportion income away from Massachusetts.5 Paradoxically, while this reduces the overall tax burden, it also reduces the “cap” on how much R&D credit they can use in a single year, potentially increasing their carryover balances.3

Navigating Special Entity Rules: S-Corps and Life Sciences

The context of the R&D credit changes slightly when dealing with specific entity classifications.

S-Corporations: The $6 Million Threshold

S-corporations in Massachusetts are not completely “pass-through” entities for excise purposes.9 If an S-corp has total receipts of $6 million or more, it is subject to an income measure tax at the corporate level.9 The Research Credit is applied against this corporate-level excise.13 Because the “Excise Before Credits” for an S-corp is often much lower than for a C-corp of similar size, S-corps frequently find themselves bumping into the $456 minimum tax floor or the 75% limit much faster than their C-corp counterparts.3

Life Sciences Refundability

For certified life sciences companies, the R&D credit transforms from a non-refundable offset into a potential cash infusion.3 Through the Massachusetts Life Sciences Center (MLSC), these firms can apply to have 90% of their unused credits refunded by the state.3 In this context, the “Excise Due (Before Credits)” is the barrier that must be cleared before the refund calculation begins.3 If a life sciences firm has $100,000 in credits and only $10,000 in excise, it uses $9,544 to hit the minimum tax and then applies to the MLSC for a refund on 90% of the remaining $90,456.3

Conclusion: Strategic Mastery of the Excise Baseline

The “Corporate Excise Due (Before Credits)” is far more than a mathematical sum; it is the definitive limit of a corporation’s immediate benefit from the Massachusetts Research Credit. By anchoring the 75% limitation and the $25,000 threshold to this pre-incentive figure, the Commonwealth maintains a sophisticated balance between revenue stability and economic stimulus.

For businesses operating in the state, the complexity of this interaction requires a multi-layered approach to tax planning. Understanding the nuances of TIR 91-8 and the aggregated group rules in 830 CMR 63.38M.2 is essential for compliance. However, mastering the strategic application of the dual carryover system—particularly the indefinite life of credits disallowed by the 75% rule—allows a firm to treat its R&D spending as a permanent, high-value asset on its balance sheet.

As Massachusetts enters a new era with single sales factor apportionment in 2025, the “Excise Before Credits” will continue to evolve, reflecting the state’s ongoing commitment to being a global leader in innovation. For the professional peer, the message is clear: the most successful R&D claims are those that look beyond the credit calculation itself and focus on the structural baseline of the excise return. In the interplay between the 75% limit and the indefinite carryover, Massachusetts offers a tax environment that reward sustained, long-term investment in the future of technology and life sciences.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/